KT-333 for Lymphoma and Cancer
Palo Alto (17 mi)Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: Kymera Therapeutics, Inc.
No Placebo Group
Trial Summary
What is the purpose of this trial?This trial is testing a new drug called KT-333 in adults with certain cancers that haven't responded to other treatments. The goal is to see if the drug is safe and how it works in the body.
Eligibility Criteria
Adults with certain types of blood cancers or solid tumors that haven't responded to standard treatments can join this trial. They should have a specific level of white blood cells, be in fair health (ECOG 0-2), and women must use effective birth control. People with brain metastases, another active cancer besides lymphoma or solid tumors, recent transplants, or unresolved treatment side effects are excluded.Inclusion Criteria
I can care for myself and am up and about more than 50% of my waking hours.
My liver and kidneys are working well.
I have T-PLL with measurable disease or atypical T cells in my blood or bone marrow.
My cancer can be measured by tests.
I have LGL leukemia with severe low white blood cell count, significant tiredness due to low red blood cell count, or need regular blood transfusions.
Exclusion Criteria
I had a stem cell transplant using my own cells less than 3 months ago.
I do not have active, uncontrolled brain metastases or specific types of meningitis.
My heart condition is currently unstable.
I have been diagnosed with Chronic Lymphocytic Leukemia.
Treatment Details
The study is testing KT-333's safety and how the body processes it in two phases: Phase 1a tests increasing doses on various cancers; Phase 1b focuses on Peripheral T-cell Lymphoma, Cutaneous T-Cell Lymphoma, Large Granular Lymphocytic Leukemia, and solid tumors to further understand KT-333's effects.
8Treatment groups
Experimental Treatment
Group I: Phase 1b Dose Expansion Solid TumorExperimental Treatment1 Intervention
KT-333 dosed IV weekly in 28 day cycles
Group II: Phase 1b Dose Expansion PTCLExperimental Treatment1 Intervention
KT-333 dosed IV weekly in 28 day cycles
Group III: Phase 1b Dose Expansion LGL-LExperimental Treatment1 Intervention
KT-333 dosed IV weekly in 28 day cycles
Group IV: Phase 1b Dose Expansion CTCLExperimental Treatment1 Intervention
KT-333 dosed IV weekly in 28 day cycles
Group V: Phase 1a Dose Escalation T-PLLExperimental Treatment1 Intervention
KT-333 dosed IV weekly in 28 day cycles
Group VI: Phase 1a Dose Escalation Solid TumorsExperimental Treatment1 Intervention
KT-333 dosed IV weekly in 28 day cycles
Group VII: Phase 1a Dose Escalation LymphomasExperimental Treatment1 Intervention
KT-333 dosed IV weekly in 28 day cycles
Group VIII: Phase 1a Dose Escalation LGL-LExperimental Treatment1 Intervention
KT-333 dosed IV weekly in 28 day cycles
Find a clinic near you
Research locations nearbySelect from list below to view details:
Ohio State University Wexner Medical CenterColumbus, OH
Hackensack University Medical Center, John Theurer Cancer CenterHackensack, NJ
UC Irvine Health-Chao Family Comprehensive Cancer CenterOrange, CA
Norton Cancer InstituteLouisville, KY
More Trial Locations
Loading ...
Who is running the clinical trial?
Kymera Therapeutics, Inc.Lead Sponsor